Manycore Tech, Inc. (KOOL)

Manycore Tech will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Cap n/a
Revenue (ttm) 378.63M
Net Income (ttm) -55.69M
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About KOOL

Manycore is a fast-growing, disruptive design software platform. Every day, our platform empowers the creation, sharing and implementation of millions of design ideas, bringing people closer to their dream homes and spaces. Being cloud-native, mobile-friendly and smart, our platform pioneers the interior design, decoration and construction industry for residential, commercial and industrial spaces. We integrate and deliver computer-aided design and building information modeling capabilities on a SaaS model, empowering businesses to deliver supe... [Read more...]

Industry Software-Application
Founded 2016
CEO Hang Chen
Employees 2,073
Stock Exchange NASDAQ
Ticker Symbol KOOL
Full Company Profile

Financial Performance

In 2020, Manycore Tech's revenue was 353.42 million, an increase of 25.19% compared to the previous year's 282.30 million. Losses were -296.61 million, 13.8% more than in 2019.

Financial numbers in CNY Financial Statements

News

Small Caps Win in September: 5 Best ETFs & Stocks

We highlight five small-cap ETFs and stocks that have outperformed in September. These could be excellent plays for investors should the same trends prevail.

Other symbols: HOVLXRXYI

4 Domestic Stocks to Buy on Global Economic Uncertainties

Global economic headwinds make it imperative to find suitable investments at home.

Other symbols: AWRCASYJJSF

ThermoGenesis Cord Blood Processing System Wins Health Canada Approval

Cesca Therapeutics shares spiked higher after the company's subsidiary, ThermoGenesis, received Health Canada approval for its AXP II System for cord blood processing.

Will Cesca Therapeutics (KOOL) Report Negative Q1 Earnings? What You Should Know

Cesca Therapeutics (KOOL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.